Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia

Hydroxyurea therapy has proven laboratory and clinical efficacies for children with sickle cell anemia (SCA). When administered at maximum tolerated dose (MTD), hydroxyurea increases fetal hemoglobin (HbF) to levels ranging from 10% to 40%. However, interpatient variability of percentage of HbF (%Hb...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ware, Russell E., Despotovic, Jenny M., Mortier, Nicole A., Flanagan, Jonathan M., He, Jin, Smeltzer, Matthew P., Kimble, Amy C., Aygun, Banu, Wu, Song, Howard, Thad, Sparreboom, Alex
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2011
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208303/
https://ncbi.nlm.nih.gov/pubmed/21876119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-364190
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky